Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 432,615
  • Shares Outstanding, K 95,500
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,200 K
  • 36-Month Beta 0.83
  • Price/Sales 118.80
  • Price/Cash Flow N/A
  • Price/Book 40.73

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.40 +114.58%
on 05/07/18
5.29 -2.65%
on 05/25/18
+2.34 (+83.27%)
since 04/25/18
3-Month
1.63 +215.95%
on 03/05/18
5.29 -2.65%
on 05/25/18
+3.31 (+179.89%)
since 02/23/18
52-Week
0.94 +447.87%
on 08/21/17
5.29 -2.65%
on 05/25/18
+3.98 (+340.17%)
since 05/25/17

Most Recent Stories

More News
ArQule Strengthens Executive Team with Two Key Appointments

ArQule, Inc. (NASDAQ: ARQL) today announced two strategic additions to its executive team, appointing Dr. Marc Schegerin as senior vice president, corporate strategy, communication and finance,...

ARQL : 5.15 (+13.69%)
What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?

Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.

ARQL : 5.15 (+13.69%)
SMMT : 13.17 (-0.38%)
PFE : 35.68 (-0.59%)
MKGAF : 96.6000 (-4.01%)
ArQule Reports First Quarter 2018 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter of 2018.

ARQL : 5.15 (+13.69%)
ArQule, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 7, 2018 / ArQule, Inc. (NASDAQ: ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 7, 2018 at 9:00 AM Eastern Time.

ARQL : 5.15 (+13.69%)
ArQule to Report First Quarter 2018 Financial Results on May 7, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the first quarter of 2018 before the market opens on Monday, May 7, 2018. The Company will hold a conference...

ARQL : 5.15 (+13.69%)
Basilea licenses late-stage oncology drug candidate derazantinib from ArQule

Basilea Pharmaceutica AG / Basilea licenses late-stage oncology drug candidate derazantinib from ArQule . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the...

ARQL : 5.15 (+13.69%)
Will ArQule (ARQL) Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in ArQule, Inc. (ARQL)

ARQL : 5.15 (+13.69%)
Recent Analysis Shows Energy Fuels, Vipshop, Tenaris S.A, ArQule, Teekay Offshore Partners, and Chicago Bridge & Iron Company N.V Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Energy Fuels Inc (NYSE:UUUU),...

ARQL : 5.15 (+13.69%)
TOO : 2.77 (+0.36%)
UUUU : 1.95 (-1.52%)
CBI : 16.39 (+1.67%)
VIPS : 11.82 (-0.92%)
TS : 37.39 (-2.07%)
ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at...

ARQL : 5.15 (+13.69%)
ArQule (ARQL) in Focus: Stock Moves 15.6% Higher

Shares of ArQule (ARQL) rose nearly 16% yesterday.

ARQL : 5.15 (+13.69%)
ENTA : 96.46 (-1.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade ARQL with:

Business Summary

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage...

See More

Key Turning Points

2nd Resistance Point 5.75
1st Resistance Point 5.45
Last Price 5.15
1st Support Level 4.69
2nd Support Level 4.23

See More

52-Week High 5.29
Last Price 5.15
Fibonacci 61.8% 3.63
Fibonacci 50% 3.12
Fibonacci 38.2% 2.60
52-Week Low 0.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar